9-Fluorenylmethyl iodoformate | 88842-53-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: 9-Fluorenylmethyl iodoformate
• 英文别名: (9H-Fluoren-9-yl)methyl carboniodidate；9H-fluoren-9-ylmethyl carboniodidate
• CAS: 88842-53-9
• 化学式: C₁₅H₁₁IO₂
• 分子量: 350.156
• InChiKey: FBAWVRHENNQQNI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  9-芴甲醇 在 吡啶 、 sodium iodide 作用下， 以 乙醚 、 乙腈 为溶剂， 反应 11.0h， 生成 9-Fluorenylmethyl iodoformate
  参考文献：
  名称：

  Reactive iodine compounds. 8. Synthesis and copper(I) cyanide-promoted cyanation of iodoformic esters

  摘要：

  DOI：

  10.1021/jo00181a005

文献信息

• [EN] TWO-CARBON LINKED ARTEMISININ-DERIVED TRIOXANE DIMERS<br/>[FR] DIMÈRES DE TRIOXANE DÉRIVÉS D'ARTÉMISININE LIÉS À DEUX ATOMES DE CARBONE
  申请人：UNIV JOHNS HOPKINS

  公开号：WO2014116642A1

  公开（公告）日：2014-07-31

  Two-carbon linked artemisinin-derived trioxane dimers and methods of their use for treating subjects infected with malaria or other parasitic infectious diseases including, but not limited to, toxoplasmic infection; subjects afflicted with psychiatric conditions associated with toxoplasmic infection; and subjects afflicted with cancer.

  两碳键合的青蒿素衍生三氧杂环二聚体及其用于治疗感染疟疾或其他寄生虫传染病的方法，包括但不限于弓形虫感染；患有与弓形虫感染相关的精神疾病的受试者；以及患有癌症的受试者。
• [EN] TRIOXANE THIOACETAL MONOMERS AND DIMERS AND METHODS OF USE THEREOF<br/>[FR] THIOACÉTALS TRIOXANES MONOMÈRES ET DIMÈRES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：UNIV JOHNS HOPKINS

  公开号：WO2013130725A1

  公开（公告）日：2013-09-06

  Monomeric and dimeric trioxane thioacetals and methods of their use for treating subjects infected with malaria or other parasitic infectious diseases including, but not limited to, toxoplasmic infection; subjects afflicted with psychiatric conditions associated with toxoplasmic infection; and subjects afflicted with cancer.

  单聚和二聚三氧杂环戊硫醚及其用于治疗感染疟疾或其他寄生虫传染病，包括但不限于弓形虫感染；患有与弓形虫感染相关的精神疾病的受试者；以及患有癌症的受试者的方法。
• Inhibitors of serine proteases
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：EP2366704A1

  公开（公告）日：2011-09-21

  The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts or mixture thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease.

  本发明涉及式（I）化合物：或其药学上可接受的盐或混合物，可抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒 NS3-NS4A 蛋白酶的活性。
• COMPOSITIONS AND METHODS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY AND RELATED DISORDERS
  申请人：Sarepta Therapeutics, Inc.

  公开号：EP3858993A1

  公开（公告）日：2021-08-04

  The present disclosure relates to compositions and methods for the treatment of Duchenne muscular dystrophy and related disorders. Modified antisense oligomers are disclosed for the treatment of Duchenne muscular dystrophy and related disorders.

  本公开涉及治疗杜氏肌营养不良症及相关疾病的组合物和方法。本发明公开了用于治疗杜氏肌营养不良症及相关疾病的修饰反义寡聚物。
• EXON SKIPPING BY PEPTIDE NUCLEIC ACID DERIVATIVES
  申请人：OliPass Corporation

  公开号：US20190337987A1

  公开（公告）日：2019-11-07

  A peptide nucleic acid derivative of Formula I is provided to tightly bind to a splice site within a pre-mRNA in a sequence specific manner. Given with excellent cell membrane permeability and strong affinity for RNA, the said peptide nucleic acid derivative induces exon skipping in cells treated with the peptide nucleic acid at sub-femtomolar concentration as “naked” oligonucleotide. The said compound shows therapeutic activity in subjects upon systemic administration even at 1 μg/Kg or less, and therefore is useful to treat a disease or symptom at affordable treatment cost.